{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:20:33Z","timestamp":1790677233794,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bulcan.2022.04.019","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T21:13:03Z","timestamp":1655759583000},"page":"844-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cancer du rein m\u00e9tastatique\u00a0: gestion des toxicit\u00e9s des combinaisons"],"prefix":"10.1016","volume":"109","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Maillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Topart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bulcan.2022.04.019_bib0355","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMe1900887","article-title":"Combination therapy as first-line treatment in metastatic renal-cell carcinoma","volume":"380","author":"Escudier","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0360","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani A-KA","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.019_bib0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11864-019-0638-1","article-title":"The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions","volume":"20","author":"Salgia","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2022.04.019_bib0370","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2022.04.019_bib0375","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2022.04.019_bib0380","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3\u00a0trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2022.04.019_bib0385","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2022.04.019_bib0390","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2022.04.019_bib0395","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0400","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Corrections to Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.bulcan.2022.04.019_bib0405","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0410","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0415","series-title":"Management of immunotherapy-related toxicities. Version 1.2022 [internet]","author":"NCCN Clinical Practice Guidelines on Oncology","year":"2022"},{"issue":"13","key":"10.1016\/j.bulcan.2022.04.019_bib0420","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3\u00a0trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2022.04.019_bib0425","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0430","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203\u00a0CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2022.04.019_bib0435","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2022.04.019_bib0440","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2022.04.019_bib0445","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2022.04.019_bib0450","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4\u00a0antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/j.bulcan.2022.04.019_bib0455","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0460","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019\u00a0ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0465","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.bpg.2020.101691","article-title":"An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management","volume":"48\u201349","author":"Smith","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0470","first-page":"19","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1\u00a0checkpoint inhibitors: a multicentre study","volume":"134","author":"Nigro","year":"2020","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0475","first-page":"1","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"10.1016\/j.bulcan.2022.04.019_bib0480","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade. Longo DL, \u00e9diteur","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2022.04.019_bib0485","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0490","unstructured":"INLYTA Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inlyta-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.04.019_bib0495","unstructured":"LENVIMA Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lenvima-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.bulcan.2022.04.019_bib0500","unstructured":"CABOMETYX Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf."},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.019_bib0505","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/j.clgc.2021.03.019","article-title":"Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma","volume":"19","author":"Rini","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0510","unstructured":"BAVENCIO Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bavencio-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.04.019_bib0515","unstructured":"OPDIVO Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf."},{"key":"10.1016\/j.bulcan.2022.04.019_bib0520","unstructured":"KEYTRUDA Summary of product characteristics. [Internet]. EUROPEAN MEDICINES AGENCY (EMA). [cit\u00e9 21\u00a0mars 2022]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf."},{"issue":"11","key":"10.1016\/j.bulcan.2022.04.019_bib0525","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0530","doi-asserted-by":"crossref","first-page":"1393e1","DOI":"10.1016\/j.cgh.2020.01.033","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0535","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Gr\u00fcnwald","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0540","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor\u2013induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.019_bib0550","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.pan.2016.02.010","article-title":"Influence of sorafenib and bevacizumab on pancreatic volume\u00a0\u2013\u00a0a monocentric CT based analysis","volume":"16","author":"Phillip","year":"2016","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.019_bib0555","doi-asserted-by":"crossref","first-page":"djw260","DOI":"10.1093\/jnci\/djw260","article-title":"Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab+ipilimumab","volume":"109","author":"Friedman","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.bulcan.2022.04.019_bib0560","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/CJI.0000000000000202","article-title":"Significance of immune-related lipase increase induced by antiprogrammed death-1\u00a0or death ligand-1\u00a0antibodies: a brief communication","volume":"41","author":"Michot","year":"2018","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0565","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-017-0303-9","article-title":"Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma","volume":"5","author":"Changizzadeh","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0570","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0575","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0580","first-page":"18","article-title":"Hypertension art\u00e9rielle et antiangiog\u00e9niques","volume":"515\u2013516","author":"Ederhy","year":"2018","journal-title":"Lett Cardiol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.019_bib0585","first-page":"385","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"issue":"18","key":"10.1016\/j.bulcan.2022.04.019_bib0590","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.019_bib0595","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"29","key":"10.1016\/j.bulcan.2022.04.019_bib0600","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","article-title":"Thrombotic events in patients with cancer receiving antiangiogenesis agents","volume":"27","author":"Zangari","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0605","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte\u00a0\u2013\u00a0associated antigen-4\u00a0prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.bulcan.2022.04.019_bib0610","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1161\/ATVBAHA.118.307742","article-title":"2016\u00a0Jeffrey M. Hoeg award lecture: immune checkpoints in atherosclerosis: toward immunotherapy for atheroprotection","volume":"38","author":"Rouwet","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"10.1016\/j.bulcan.2022.04.019_bib0615","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2007.12.8710","article-title":"Reversible posterior leukoencephalopathy syndrome induced by sunitinib","volume":"25","author":"Mart\u00edn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.019_bib0620","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.04.019_bib0625","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1\u00a0therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0630","doi-asserted-by":"crossref","first-page":"viii405","DOI":"10.1093\/annonc\/mdy288.014","article-title":"Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1","volume":"29","author":"Kfoury","year":"2018","journal-title":"Ann Oncol"},{"issue":"4\u20135","key":"10.1016\/j.bulcan.2022.04.019_bib0635","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","article-title":"A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients","volume":"46","author":"Cortellini","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0640","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2022.04.019_bib0645","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12894-019-0481-5","article-title":"Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Urol"},{"issue":"11","key":"10.1016\/j.bulcan.2022.04.019_bib0650","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2022.04.019_bib0655","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000499089","article-title":"Axitinib-induced hypothyroidism as a predictor of long-term survival in patients with metastatic renal cell carcinoma","volume":"102","author":"Takada","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.bulcan.2022.04.019_bib0660","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1\u00a0antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2022.04.019_bib0665","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41571-018-0006-2","article-title":"The gut microbiota influences anticancer immunosurveillance and general health","volume":"15","author":"Routy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6371","key":"10.1016\/j.bulcan.2022.04.019_bib0670","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u00a0\u2013\u00a0based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6382","key":"10.1016\/j.bulcan.2022.04.019_bib0675","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1126\/science.aar6918","article-title":"The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies","volume":"359","author":"Zitvogel","year":"2018","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.bulcan.2022.04.019_bib0680","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.019_bib0685","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2022.04.019_bib0690","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1\u00a0inhibitor\u00a0\u2013\u00a0related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2022.04.019_bib0695","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French endocrine society guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2022.04.019_bib0350","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bulcan.2019.02.003","article-title":"Endocrinopathies induites par l\u2019immunoth\u00e9rapie\u00a0: synth\u00e8se du consensus 2018\u00a0de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019endocrinologie","volume":"106","author":"Castinetti","year":"2019","journal-title":"Bull Cancer (Paris)"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122001977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:51Z","timestamp":1757792151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122001977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":70,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0007455122001977"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.019","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer du rein m\u00e9tastatique\u00a0: gestion des toxicit\u00e9s des combinaisons","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}